Brandon Lee, MD
Ophthalmology · Kingsport, TNNPI 1225080021
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (55.2%), travel and lodging and education — rather than concentrated in one kind of arrangement. Alcon accounts for 63.9% of it on its own, with 16 other manufacturers making up the rest. Reporting peaked in 2019 at $1,458 and has fallen 93.1% since, to $100 in 2025.
Across 38 payments — averaging $52.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$1K
- Amgen$147
- Johnson & Johnson Surgical Vision, Inc.$126
- AbbVie$120
- Rayner Intraocular Lenses Limited$53
- Ivantis, Inc$45
- plus $236 from 11 others
Across 64 payments — averaging $544.38 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novo Nordisk AS$35K
What the payments were for
- Travel & lodging$88944%
- Food & beverage$1,11155%
- Education$131%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 11 | $1,286 |
| Amgen | 1 | $147 |
| Johnson & Johnson Surgical Vision, Inc. | 4 | $126 |
| AbbVie | 4 | $120 |
| Rayner Intraocular Lenses Limited | 3 | $53 |
| Ivantis, Inc | 1 | $45 |
| Rxsight Inc | 2 | $41 |
| Genentech USA, Inc. | 2 | $40 |
| Omeros Corporation | 2 | $33 |
| Harrow Eye, LLC | 1 | $24 |
| Eyepoint US, Inc. | 1 | $21 |
| GSK | 1 | $16 |
| Novartis | 1 | $15 |
| Sight Sciences, Inc. | 1 | $14 |
| Regeneron Healthcare Solutions, Inc. | 1 | $13 |
| Shire North American Group Inc | 1 | $11 |
| Iridex Corporation | 1 | $8 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,013 in reported general payments places this provider in the 55th percentile of 323 ophthalmology providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 59 | $71,303 |
| LumiganBimatoprost | 73 | $27,526 |
| Cyclosporine | 38 | $18,675 |
| XiidraLifitegrast | 13 | $17,956 |
| CombiganBrimonidine Tartrate/Timolol | 69 | $14,881 |
| RhopressaNetarsudil Mesylate | 14 | $6,951 |
| RocklatanNetarsudil Mesylat/Latanoprost | 19 | $6,029 |
| Latanoprost | 378 | $3,805 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 23 | $1,947 |
| Travoprost | 16 | $1,647 |
| Prednisolone Acetate | 43 | $1,403 |
| Brimonidine Tartrate | 31 | $1,058 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 50 | $841 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 61 | $742 |
| Ketorolac Tromethamine | 17 | $379 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan | $120 | $113,710201 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 323 ophthalmology providers in Tennessee.
Other ophthalmology in Kingsport
- Deborah ShermanNashville$3M
- Melissa ToyosMemphis$1.3M
- Rolando ToyosMemphis$809K
- Brian BiesmanNashville$630K
- Brian FowlerMemphis$206K
- Edward ChaumNashville$158K
- Brian JerkinsMemphis$150K
- James FreemanMemphis$141K
- Michael PattersonCrossville$138K
- John FreemanMemphis$136K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.